Press Releases

Sep 13, 2022 9:30am EDT

TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®

Aug 22, 2022 8:30am EDT

TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Jul 25, 2022 8:30am EDT

TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit

Jul 08, 2022 8:30am EDT

TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"

Jun 07, 2022 4:00pm EDT

TC Biopharm Announces Closing of $4 Million Underwritten Public Offering

Jun 02, 2022 6:10pm EDT

TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering

May 31, 2022 10:00am EDT

TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally

May 23, 2022 8:30am EDT

Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market

May 18, 2022 8:30am EDT

TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts

May 03, 2022 8:30am EDT

TC BioPharm Invited to Present at LD Micro Conference

rss_feed News RSS

This website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our Privacy Policy.

I Accept